Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Axi-cel delivers similar outcomes regardless of ASCT-eligibility in second line R/R LBCL: Combined data from ZUMA-7 and ALYCANTE

Roch Houot, Pablo Arija, Emmanuel Bachy, Guillaume Cartron, François-Xavier Gros, Franck Morschhauser, Cedric Portugues, Catherine Thieblemont, Markqayne Ray, Yin Yang, Sante Cundari, Camille Linot, Divyesh Mistry, Martijn Simons, Anna Gittfried, François Lemonnier

Blood (2025) 146 (Supplement 1): 3714.

https://doi.org/10.1182/blood-2025-3714

Published: 2025

Journal Articles

Center effect on large B-cell lymphoma outcome in frontline prospective Phase II and III trials : A lysa study

Tristan Robert-Van Houtteghem, Marguerite Fournier, Fabrice Jardin, Pierre Feugier, François Lemonnier, Loic Ysebaert, Franck Morschhauser, Laure Lebras, Cedric Rossi, Vincent Ribrag, Catherine Thieblemont, Aurelien Belot, Emmanuel Bachy

Blood (2025) 146 (Supplement 1): 4495.

https://doi.org/10.1182/blood-2025-4495

Published: 2025

Journal Articles

Safety and efficacy of CD3xCD20 bispecific antibody for the treatment of primary and secondary central nervous system lymphoma patients: A multicentric retrospective study

Blood (2025) 146 (Supplement 1): 1018.

https://doi.org/10.1182/blood-2025-1018

Published: 2025

Journal Articles

Valemetostat monotherapy in patients with relapsed or refractory B-cell lymphoma: Final results of the Phase 2 valym study from the lysa

Blood (2025) 146 (Supplement 1): 1797.

https://doi.org/10.1182/blood-2025-1797

Published: 2025

Journal Articles

PlatΤform: A multicenter, multi-arm, academic platform trial evaluating novel agents and combinations in relapsed or refractory peripheral T-cell lymphomas

David Sibon, Doriane Cavalieri, Mad-Helenie Elsensohn, Eve Gehlkopf, Delphine Leduc, Corinne Haioun, François Lemonnier

Blood (2025) 146 (Supplement 1): 3657.

https://doi.org/10.1182/blood-2025-3657

Published: 2025

Journal Articles

Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy as second-line treatment for Relapsed/Refractory large B-cell lymphoma: primary analysis of the randomized, pivotal DALY 2-EU study.

Blood (2025) 146 (Supplement 1): 669.

https://doi.org/10.1182/blood-2025-669

Published: 2025

Journal Articles

Prognostic value of combining beta-2-microglobulin and total metabolic tumor volume in patients with follicular lymphoma: A post-hoc analysis of the relevance trial

Blood (2025) 146 (Supplement 1): 5361.

https://doi.org/10.1182/blood-2025-5361

Published: 2025

Journal Articles

Circulating CD161high CD8 T cells at leukapheresis are associated with reduced risk of progression at 12 months (PFS12) in large B-cell lymphoma treated by axicabtagene ciloleucel: Results from the Phase 2 alycante study (LYSA)

Mikael Roussel, Juliette Ferrant, Ilenia Camille Manbangui, Simon Le Gallou, Charles BROTTIER, Delphine Rossille, Joelle DULONG, Marie-Helene Delfau, Alexis Claudel, François Lemonnier, Roch Houot, Camille Laurent, Karin Tarte

Blood (2025) 146 (Supplement 1): 5332.

https://doi.org/10.1182/blood-2025-5332

Published: 2025

Journal Articles

Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment

Blood (2025) 146 (8): 913–925.

https://doi.org/10.1182/blood.2024027727

Published: 2025

Includes: Supplemental data

Journal Articles

PRIMAVERA: A Modular Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed/Refractory Hematologic Malignancies

Blood (2024) 144 (Supplement 1): 1674.2.

https://doi.org/10.1182/blood-2024-203060

Published: 2024

Journal Articles

Single-Cell Atlas of Diffuse Large B-Cell Lymphoma Reveals Integrated Malignant B Cell and Tumor Microenvironment Characteristics Associated with Clinical Response

Blood (2024) 144 (Supplement 1): 1597.

https://doi.org/10.1182/blood-2024-209815

Published: 2024

Journal Articles

Valemetostat Monotherapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma: Primary Results of the Phase 2 Valym Study from the Lysa

Blood (2024) 144 (Supplement 1): 4479.

https://doi.org/10.1182/blood-2024-193960

Published: 2024

Journal Articles

Health-Related Quality of Life after Axi-Cel As a Second-Line Therapy in Patients with High-Risk Relapsed/Refractory Large B-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Results of the Alycante Phase II Trial

Blood (2024) 144 (Supplement 1): 4505.

https://doi.org/10.1182/blood-2024-200614

Published: 2024

Journal Articles

A Single Cell Atlas of Diffuse Large B Cell Lymphomas Reveals Distinct Cellular States Predictive of Outcomes

Blood (2023) 142 (Supplement 1): 848.

https://doi.org/10.1182/blood-2023-173929

Published: 2023

Journal Articles

Tazemetostat in Combination with R-CHOP in Patients with High-Risk, Frontline Follicular Lymphoma (Epi-RCHOP): A Phase II Study from the Lysa

Blood (2023) 142 (Supplement 1): 297.

https://doi.org/10.1182/blood-2023-185057

Published: 2023

Journal Articles

Axicabtagene Ciloleucel As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Primary Analysis of Alycante, a Phase 2 Lysa Study

Roch Houot, Emmanuel Bachy, Guillaume Cartron, François-Xavier Gros, Franck Morschhauser, Lucie Oberic, Thomas Gastinne, Pierre Feugier, Remy Dulery, Catherine Thieblemont, Magalie Joris, Francisco Llamas-Gutierrez, Emmanuel Itti, Cedric Menard, Yassine Al-Tabaa, Clement Bailly, Marie-Helene Delfau, Camille Laurent, Francois Lemonnier

Blood (2022) 140 (Supplement 1): 410–411.

https://doi.org/10.1182/blood-2022-156626

Published: 2022

Journal Articles

Oral Azacytidine in Patients with Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma: Final Analysis of the Oracle Phase III Study

Blood (2022) 140 (Supplement 1): 2310–2312.

https://doi.org/10.1182/blood-2022-156789

Published: 2022

Journal Articles

Trial in Progress: A Randomized Phase II Study of MB-CART2019.1 Compared to Standard of Care Therapy in Patients with Relapsed/Refractory DLBCL Ineligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation - DALY 2-EU Trial

Peter Borchmann, Peter Vandenberghe, Alvaro Urbano-Ispizua, Corinne Haioun, Francois Lemonnier, Laimonas Griskevicius, Sébastien Maury, Silke Holtkamp, Birte Friedrichs, Gregor Zadoyan, Linda Hanssens, Toon Overstijns, Mario Assenmacher, Ulf Bethke, Iris Bürger, Olaf Reer, Ulrich Jaeger, Marie José Kersten

Blood (2022) 140 (Supplement 1): 12784–12785.

https://doi.org/10.1182/blood-2022-164650

Published: 2022

Journal Articles

Integrative Study of a High-Grade B-Cell Lymphoma Cohort of 45 Patients: A Single Institution Real Life Study

Louise Roulin, Elsa Poullot, Paul Blanc-Durand, Cyrielle Robe, Francois Lemonnier, Fabien Le Bras, Romain Gounot, Karim Belhadj, Jehan Dupuis, Mohammad Hammoud, Taoufik El Gnaoui, Sebastien Mule, Christiane Copie Bergman, Thierry Molina, Marie Helene Delfau Larue, Emmanuel Itti, Philippe Gaulard, Corinne Haioun

Blood (2021) 138 (Supplement 1): 4576.

https://doi.org/10.1182/blood-2021-152627

Published: 2021

Journal Articles

Single-Cell and Spatial Analyses Characterize Distinct Subsets of Malignant T Cells in Angioimmunoblastic T Cell Lymphoma

Francois Lemonnier, Chuang Dong, Bruno Tesson, Laurine Gil, Noudjoud Attaf, Diana-Laure Mboumba, Philippe Gaulard, Pierre Milpied

Blood (2021) 138 (Supplement 1): 2393.

https://doi.org/10.1182/blood-2021-147246

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Axi-cel delivers similar outcomes regardless of ASCT-eligibility in second line R/R LBCL: Combined data from ZUMA-7 and ALYCANTE

Center effect on large B-cell lymphoma outcome in frontline prospective Phase II and III trials : A lysa study

Safety and efficacy of CD3xCD20 bispecific antibody for the treatment of primary and secondary central nervous system lymphoma patients: A multicentric retrospective study

Valemetostat monotherapy in patients with relapsed or refractory B-cell lymphoma: Final results of the Phase 2 valym study from the lysa

PlatΤform: A multicenter, multi-arm, academic platform trial evaluating novel agents and combinations in relapsed or refractory peripheral T-cell lymphomas

Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy as second-line treatment for Relapsed/Refractory large B-cell lymphoma: primary analysis of the randomized, pivotal DALY 2-EU study.

Prognostic value of combining beta-2-microglobulin and total metabolic tumor volume in patients with follicular lymphoma: A post-hoc analysis of the relevance trial

Circulating CD161high CD8 T cells at leukapheresis are associated with reduced risk of progression at 12 months (PFS12) in large B-cell lymphoma treated by axicabtagene ciloleucel: Results from the Phase 2 alycante study (LYSA)

Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment

PRIMAVERA: A Modular Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed/Refractory Hematologic Malignancies

Single-Cell Atlas of Diffuse Large B-Cell Lymphoma Reveals Integrated Malignant B Cell and Tumor Microenvironment Characteristics Associated with Clinical Response

Valemetostat Monotherapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma: Primary Results of the Phase 2 Valym Study from the Lysa

Health-Related Quality of Life after Axi-Cel As a Second-Line Therapy in Patients with High-Risk Relapsed/Refractory Large B-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Results of the Alycante Phase II Trial

A Single Cell Atlas of Diffuse Large B Cell Lymphomas Reveals Distinct Cellular States Predictive of Outcomes

Tazemetostat in Combination with R-CHOP in Patients with High-Risk, Frontline Follicular Lymphoma (Epi-RCHOP): A Phase II Study from the Lysa

Axicabtagene Ciloleucel As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Primary Analysis of Alycante, a Phase 2 Lysa Study

Oral Azacytidine in Patients with Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma: Final Analysis of the Oracle Phase III Study

Trial in Progress: A Randomized Phase II Study of MB-CART2019.1 Compared to Standard of Care Therapy in Patients with Relapsed/Refractory DLBCL Ineligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation - DALY 2-EU Trial

Integrative Study of a High-Grade B-Cell Lymphoma Cohort of 45 Patients: A Single Institution Real Life Study

Single-Cell and Spatial Analyses Characterize Distinct Subsets of Malignant T Cells in Angioimmunoblastic T Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only